Journal
BIOMARKERS
Volume 17, Issue 8, Pages 671-691Publisher
INFORMA HEALTHCARE
DOI: 10.3109/1354750X.2012.715672
Keywords
Antioxidant; cancer; biomarker; patients; response; oxidative stress
Categories
Funding
- NIH/NCI [CA114365]
Ask authors/readers for more resources
This review summarizes clinical studies in which glutathione was measured in tumor tissue from patients with brain, breast, gastrointestinal, gynecological, head and neck and lung cancer. Glutathione tends to be elevated in breast, ovarian, head and neck, and lung cancer and lower in brain and liver tumors compared to disease-free tissue. Cervical, colorectal, gastric, and esophageal cancers show both higher and lower levels of tumor glutathione. Some studies show an inverse relationship between patient survival and tumor glutathione. Based on this survey, we recommend approaches that may improve the clinical value of glutathione as a biomarker.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available